RecruitingNot Applicable

BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction

China774 participantsStarted 2020-10-01

Plain-language summary

To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients (\>18 years old); * Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization; * Patients must have received in-hospital CEM for at least 5 days; * Patients must give informed consent. Exclusion Criteria: * Patients with a medical history of pre-existing AF; * Patients with a medical history of rheumatic valvular disease; * Patients with a medical history of sick sinus syndrome; * Patients undergoing emergent coronary artery bypass surgery; * Patients who suffer malignant tumors with an expected lifetime less than 1 year ; * Patients who refuse to receive CEM during hospitalization and the data of heart rhythm cannot be retrieved; * Patients who refuse to receive percutaneous coronary intervention (PCI) or have contraindications for PCI; * Patients who have died during the index hospitalization.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

All-cause death

Timeframe: up to 1 year

Trial details

NCT IDNCT04528511

SponsorShanghai 10th People's Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12-31

Contact for this trial

Jiachen Luo, M.D., Ph.D.

+86-188-0179-0469 messichen@tongji.edu.cn

View on ClinicalTrials.gov More Atrial Fibrillation New Onset trials